The continuous emergence of tumor immunotherapy methods based on CD8+T cells marks the progress of CD8+T cells in anti-tumor therapy, and their value and potential in clinical transformation are highly concerning (Dolina et al., 2021). This evidence concerns the gene CD8A and neoplasm.